Leqembi (lecanemab)was approved in July 2023, andKinsula (donanemab)one year later.
The slow implementation of these new treatments highlights ongoing hurdles and logistical challenges in making them accessible to patients.
Before starting treatment, patients must undergo extensive testing.
Photo Illustration by Amelia Manley for Verywell Health; Getty Images
This includes cognitive assessments and either aspinal tapor PET imaging to confirm the presence of amyloid plaques.
(Although some doctors use blood tests, none have been FDA-approved.)
Additionally, doctors must screen for potential drug interactions.
These treatments are also only approved for people with early-stage Alzheimers or mild cognitive impairment.
Kisunla is given every four weeks until the amyloid is cleared, as measured by a scan.
If a PET scan shows minimal levels of amyloid, treatment is stopped.
2025;104(3):e210217.
doi:10.1212/WNL.0000000000210217
Eisai.Tests you should know about.
UCHealth.New blood tests for Alzheimers may allow for earlier detection of the terrible disease.
But how much will Alzheimers blood tests cost, and who should get them?.
Mayo Clinic Alzheimers Disease Treatment Clinic.Overview.
